Sign inJoin waitlistJoin the waitlist

Gabriel Mannis

Medical Director, Stanford Hospital Inpatient Hematology Service · Stanford Health Care

Credentials: · · ·

History

Stanford Hospital Inpatient Hematology Service · Stanford Health Care
Present
Stanford Health Care
Present
Stanford Health Care
Present

UCSF Hematology and Medical Oncology Fellowship (2014) CA
2011–2014
Internal Medicine
University of California-San Francisco
2010–2011
University of California, Davis, School of Medicine
2004–2008

Research

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 359 citations
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Blood · 2020 · 315 citations

Rebecca Olin
16 papers
Aaron Logan
15 papers
Charalambos Andreadis
13 papers
Tian Zhang
13 papers
Amir Fathi
11 papers
Lloyd Damon
11 papers
Thomas Martin
11 papers
Alice Mims
10 papers
Alexander Perl
9 papers
Daniel Pollyea
9 papers
Richard Stone
9 papers
Brian Jonas
8 papers

Clinical trials

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Site PI · Recruiting · Phase 1
Crossbow Therapeutics, Inc.
2025–2027
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Site PI · Recruiting · Phase 1, Phase 2
Stanford University
2025–2028
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1, Phase 2
Aptose Biosciences Inc.
2019–2027